Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Liu, Joyce F
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. [electronic resource] - JAMA oncology 12 2019 - 1731-1738 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
2374-2445
10.1001/jamaoncol.2019.3343 doi
Administration, Intravenous
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Bevacizumab--administration & dosage
Carcinoma, Ovarian Epithelial--drug therapy
Drug Administration Schedule
Drug Synergism
Female
Humans
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Nivolumab--administration & dosage
Survival Analysis
Treatment Outcome
United States
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. [electronic resource] - JAMA oncology 12 2019 - 1731-1738 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
2374-2445
10.1001/jamaoncol.2019.3343 doi
Administration, Intravenous
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Bevacizumab--administration & dosage
Carcinoma, Ovarian Epithelial--drug therapy
Drug Administration Schedule
Drug Synergism
Female
Humans
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Nivolumab--administration & dosage
Survival Analysis
Treatment Outcome
United States